AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

AbbVie's immunology franchise remains a key driver of growth, with Skyrizi and Rinvoq continuing to gain market share and exceed analyst expectations. These two drugs are crucial to the company's ...

AbbVie's immunology franchise remains a key driver of growth, with Skyrizi and Rinvoq continuing to gain market share and exceed analyst expectations. These two drugs are crucial to the company's ...